Benzimidazolidophosphate | 93755-82-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: Benzimidazolidophosphate
• 英文别名: 1-(benzimidazolyl) phosphoric acid；(1H-Benzo[d]imidazol-1-yl)phosphonic acid；benzimidazol-1-ylphosphonic acid
• CAS: 93755-82-9
• 化学式: C₇H₇N₂O₃P
• 分子量: 198.118
• InChiKey: IULVOCCQRPPCPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  苯并咪唑 在 四磷十氧化物 作用下， 以 氯仿 为溶剂， 以92%的产率得到Benzimidazolidophosphate
  参考文献：
  名称：

  Zavlin, P. M.; Efremov, D. A.; Gugkaev, A. V., Journal of general chemistry of the USSR, 1990, vol. 60, # 5, p. 1054 - 1055

  摘要：

  DOI：

文献信息

• NOVEL BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
  申请人：Botton Gerard

  公开号：US20100286129A1

  公开（公告）日：2010-11-11

  The present invention relates to novel benzimidazole-dihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, to processes for the preparation thereof and to the use thereof in therapy, especially for the treatment of diabetes.

  本发明涉及作为果糖-1,6-二磷酸酶抑制剂的新型苯并咪唑-二氢噻二唑酮衍生物，以及其制备方法和在治疗中的用途，特别是用于糖尿病的治疗。
• Interaction Between Phosphoric Anhydride and Organic Compounds with Prototropic Properties
  作者：D.A. Efremov、J.C. Tebby、P.M. Zavlin

  DOI：10.1080/10426509608545191

  日期：1996.1

  Abstract: Phosphoric anhydride has been shown to interact with organic compounds with prototropic properties, i.e. unsubstituted and monosubstituted amides, pyrimidinetriones, azoles and esters. Some products of phosphorylation have a tendency to exhibit phosphorotropy (1-3 and 1-4 shifts).

  摘要：磷酸酐已被证明与具有质子性质的有机化合物相互作用，即未取代和单取代的酰胺、嘧啶三酮、唑类和酯类。一些磷酸化产物倾向于表现出磷光性（1-3 和 1-4 位移）。
• Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them
  申请人：Merck Sante

  公开号：EP1752450A1

  公开（公告）日：2007-02-14

  Imidazole derivatives of formula (I): wherein R1, R2a, R2b, A, V and W are as defined in the description, as inhibitors of fructose-1,6-bisphosphatase, their preparation process and their use in the prevention or treatment of diabetes, and other diseases where the inhibition of gluconeogenesis, control of blood glucose levels, reduction in glycogen stores, or reduction in insulin levels is beneficial and diseases related to the insulin resistance syndrome.

  式(I)的咪唑衍生物，其中R1、R2a、R2b、A、V和W的定义如描述所述，作为果糖-1,6-二磷酸酶抑制剂，它们的制备过程以及它们在预防或治疗糖尿病和其他疾病中的应用，这些疾病中的葡萄糖新生抑制、血糖水平控制、糖原储量减少或胰岛素水平降低是有益的，以及与胰岛素抵抗综合症相关的疾病。
• Novel Imidazolecarboxamide Derivatives as Fructose-1,6-Bisphosphatase Inhibitors, and Pharmaceutical Compositions Comprising Same
  申请人：Moinet Gerard

  公开号：US20080207720A1

  公开（公告）日：2008-08-28

  The invention relates to the compounds of the general formula (I): in which A, D, R, R 1 and X are as defined in the description, to a process for the preparation thereof and to the therapeutic use thereof in the treatment of pathologies associated with insulin resistance syndrome.

  本发明涉及一般式（I）的化合物： 其中A，D，R，R1和X如描述中定义，以及其制备方法和在治疗与胰岛素抵抗综合征相关的病理方面的治疗用途。
• Imidazole Derivatives as Fructose-1,6-Bisphosphatase Inhibitors and Pharmaceutical Compositions Containing Them
  申请人：Carniato Denis

  公开号：US20080312299A1

  公开（公告）日：2008-12-18

  Imidazole derivatives of formula (I) wherein R 1 , R 2a , R 2b , A, V and W are as defined in the description, as inhibitors of fructose-1,6-bisphosphatase, their preparation process and their use in the prevention or treatment of diabetes, and other diseases where the inhibition of gluconeogenesis, control of blood glucose levels, reduction in glycogen stores, or reduction in insulin levels is beneficial and diseases related to the insulin resistance syndrome.

  公式（I）的咪唑衍生物，其中R1，R2a，R2b，A，V和W在说明中定义，作为果糖-1,6-二磷酸酶的抑制剂，它们的制备过程以及它们在预防或治疗糖尿病和其他疾病中的用途，其中抑制糖异生作用，控制血糖水平，减少糖原储存或降低胰岛素水平是有益的，以及与胰岛素抵抗综合症相关的疾病。